Episurf Medical: Update on Episealer® Patellofemoral System for the US market
Episurf Medical (NASDAQ: EPIS B) today announces that the development of the company’s Episealer® Patellofemoral System is progressing according to plan. The previously communicated plan to submit a 510(k) application before the end of the year to the US FDA for US market clearance is still valid. The design for the system is now set and final device testing is presently being conducted. Episealer® Patellofemoral System is an implant system with two implants for treatment of chondral and osteochondral lesions in the knee joint. Simultaneously, the company is preparing for a commercial